MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders.

MSP powerhouse Ahead has purchased MBX Systems, owner of the proprietary software platform Hatch. Here are Ahead’s bullish integration ideas for MBX. Enterprise cloud MSP superstar Ahead has ...

MBX stock opened at $7.76 on Friday. The company’s 50-day moving average price is $9.89. MBX Biosciences, Inc. has a 52-week low of $7.25 and a 52-week high of $27.50. About MBX Biosciences ...

Also, CEO P. Kent Hawryluk acquired 50,000 shares of MBX Biosciences stock in a transaction on Tuesday, February 4th. The stock was purchased at an average price of $10.69 per share, with a total ...